全球 HER2 測試市場 - 市場規模（依細分市場）、佔有率、監管、償付、預測（~2033年）

本報告研究和分析了全球 HER2 檢測市場，提供有關主要參與者、市場佔有率、主要趨勢、創新產品和技術以及競爭格局的資訊。

市場模型的主要內容如下。

已上市的 HER2 測試和不斷變化的競爭格局

• 對主要產業趨勢的考察
• 按 HER2 測試市場細分的年收入和市場前景（2015-2033年）
• 有關單位數量、平均售價和市場價值的市場級資料

全球、區域和國家層面的特定市場考察

• 依地區細分全球趨勢的特定市場定性資訊和國家考察
• HER2檢測市場的SWOT分析
• HER2檢測市場競爭動態的考察與趨勢

掌握包括醫療保健系統概述真實情況，促進市場了解。市場進入部分還提供有關償付政策和監管環境的訊息，能夠更深入地研究市場動態。

• 各國醫療保健系統概覽
• 依國家/地區劃分的償付政策
• 各國醫療科技監理狀況

目標公司

• Abbott Laboratories
• Agilent Technologies Inc
• Amoy Diagnostics Co Ltd
• Biocare Medical LLC
• MilliporeSigma + Sigma Aldrich
• Foundation Medicine Inc
• Illumina Inc
• Leica Biosystems Nussloch GmbH
• medac GmbH
• New England Biolabs Inc
• Qiagen NV
• Oxford Gene Technology Inc
• Thermo Fisher Scientific Inc
• 其他

HER2 Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Human epidermal growth factor receptor 2 (HER2) tests, using biopsied tissue, typically breast tissue, are carried out to detect over-expression of the HER2 protein, or additional copies HER2/neu gene encoding for the protein; the outcome of which may guide therapies to treat certain breast cancers, along with some ovarian cancers, uterine cancers, stomach cancers, and lung cancers.

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor belonging to the family of epidermal growth factor receptors (EGFRs). The protein is encoded by the HER2 (ERBB2) gene, which is located on the long arm of chromosome 17 (17q12-21.32). The inappropriate activation of HER2 is associated with the development of several malignancies, including breast, gastric, ovarian, colorectal, pancreatic, and endometrial cancers. An accurate evaluation of HER2 status is crucial for identification of patients who would most likely benefit from targeted anti-HER2 therapies.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed HER2 Tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total HER2 tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for HER2 Tests market.
• Competitive dynamics insights and trends provided for HER2 Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Agilent Technologies Inc, Amoy Diagnostics Co Ltd,Biocare Medical LLC, MilliporeSigma + Sigma Aldrich, Foundation Medicine Inc, Illumina Inc, Leica Biosystems Nussloch GmbH, medac GmbH,New England Biolabs Inc,Qiagen NV,Oxford Gene Technology Inc,Thermo Fisher Scientific Inc, Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the HER2 Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving HER2 Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HER2 Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific HER2 Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.